Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1

Antimicrob Agents Chemother. 1985 Apr;27(4):655-6. doi: 10.1128/AAC.27.4.655.

Abstract

The penetration of aztreonam into cerebrospinal fluid was 7 to 15% and 9 to 25%, respectively, in experimental Haemophilus influenzae type b and Escherichia coli K1 meningitis. Aztreonam was effective in reducing the number of organisms in cerebrospinal fluid after single-dose and continuous infusion administration, and the median bactericidal titers in cerebrospinal fluid were 1:32 against both meningeal pathogens.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / cerebrospinal fluid
  • Anti-Bacterial Agents / therapeutic use*
  • Aztreonam
  • Escherichia coli Infections / drug therapy*
  • Male
  • Meningitis / drug therapy*
  • Meningitis / etiology
  • Meningitis, Haemophilus / drug therapy*
  • Microbial Sensitivity Tests
  • Rabbits

Substances

  • Anti-Bacterial Agents
  • Aztreonam